Discover a study where results suggest a statistically significant association between dupilumab and psoriasis, although the clinical impact may be limited.

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Biological drugs have improved the lives of many people with severe asthma. However, a new study from Karolinska Institutet ...

This new agreement marks the fourth product in the partnership and introduces a potential cost-effective alternative to one ...

A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

Key findings of subgroup analyses included an observed increased psoriasis risk in patients without atopic comorbidities (HR 1.42, 95% CI 1.06-1.89) and those with pretreatment immunoglobulin E (IgE) ...